AI Article Synopsis

Article Abstract

Importance: Azathioprine hypersensitivity syndrome can present clinically and histopathologically like Sweet syndrome. Shared clinical features include fever, constitutional symptoms, prompt response to systemic corticosteroid therapy, neutrophilia, and abrupt onset of erythematous cutaneous lesions. Histologically, both azathioprine hypersensitivity syndrome and Sweet syndrome are rich in neutrophils.

Observations: An 81-year-old woman with Crohn disease presented with fever and an acute eruption of plaques on her extremities within 2 weeks of starting treatment with azathioprine. Laboratory evaluation was notable for leukocytosis and neutrophilia. Skin biopsy of an erythematous plaque on the thigh demonstrated a suppurative folliculitis. Azathioprine treatment was discontinued resulting in resolution of the clinical lesions within 5 days. Our case was compared with 18 cases with similar clinical features.

Conclusions And Relevance: We report a case of azathioprine hypersensitivity syndrome and review the literature on azathioprine-induced eruptions with features of Sweet syndrome. Our patient's distribution of lesions on the extremities and the finding of suppurative folliculitis on histopathology were not classical for Sweet syndrome. Azathioprine hypersensitivity syndrome seems to be a neutrophil-driven dermatosis; therefore, many overlapping features with Sweet syndrome are not surprising. Due to the potential for anaphylaxis with azathioprine rechallenge, a better term for a Sweetlike presentation in the setting of azathioprine administration is azathioprine hypersensitivity syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2013.137DOI Listing

Publication Analysis

Top Keywords

azathioprine hypersensitivity
20
hypersensitivity syndrome
20
sweet syndrome
20
azathioprine
10
syndrome
10
suppurative folliculitis
8
features sweet
8
hypersensitivity
5
sweet
5
neutrophilic dermatosis
4

Similar Publications

Introduction: Both cellular and humoral responses are important for vaccine protection, but recommendations on immunosuppressants in dermatology are largely based on pre-pandemic experiences. This study aimed to investigate the impacts of immunosuppressants on humoral and cellular immunogenicity to COVID-19 vaccinations in pemphigus patients.

Methods: SARS-CoV-2-naïve pemphigus patients and age-, and sex-matched healthy controls were recruited from multiple tertiary medical centers during 2021-2023.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed the long-term safety of dupilumab, a drug for atopic dermatitis (AD), compared to conventional systemic treatments like azathioprine and methotrexate using electronic health records.
  • Findings showed that dupilumab had a lower risk of various adverse effects, including infections and type 2 inflammatory diseases, compared to other treatments.
  • However, the risk of conjunctivitis was higher in patients treated with dupilumab compared to those on mycophenolate mofetil and methotrexate, prompting the need for further research to confirm these results.
View Article and Find Full Text PDF
Article Synopsis
  • Hypereosinophilic syndrome (HES) leads to high levels of eosinophils in the blood and tissues, causing organ damage, with gastrointestinal issues being a common manifestation.
  • A 28-year-old female patient suffered from severe gastrointestinal symptoms and was diagnosed with idiopathic HES and eosinophilic esophagitis, resistant to multiple treatments.
  • After starting dupilumab, a recently FDA-approved treatment, the patient achieved remission, resolving her gastrointestinal issues and allowing her to return to a normal diet without needing total parenteral nutrition.
View Article and Find Full Text PDF
Article Synopsis
  • Dupilumab is a biologic medication approved for treating atopic dermatitis in kids aged 6 months to 17 years, and the study focused on its effects on associated health issues in these patients.* -
  • Using electronic health records, researchers matched 3,575 pediatric patients receiving dupilumab with the same number receiving other treatments, assessing the emergence of new health problems.* -
  • Results showed that dupilumab significantly reduced the risk of various comorbidities like asthma, infections, and psychiatric disorders, especially in younger children (0-5 years).*
View Article and Find Full Text PDF

A case report of reversible left ventricular dysfunction due to azathioprine hypersensitivity syndrome.

Eur Heart J Case Rep

August 2024

Cardiology Department, Kantonsspital St. Gallen, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland.

Background: Hypersensitivity reaction is a rare side effect during immunosuppressive treatment with azathioprine (AZA). Some cases of cardiac involvement have already been reported but causality is notoriously difficult to prove.

Case Summary: We present the case of a 68-year-old man with two episodes of reversible left ventricular (LV) dysfunction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!